EMA Authorised: Kygevvi (doxecitine;Doxribtimine) — UCB Pharma

View source ↗

Summary

The EMA authorized Kygevvi (doxecitine; Doxribtimine) from UCB Pharma for mitochondrial diseases, with orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mitochondrial Diseases

Drugs mentioned

• KYGEVVI (DOXECITINE AND DOXRIBTIMINE)

Snippet

Status: Authorised. Therapeutic area: Mitochondrial Diseases. MAH: UCB Pharma. Decision date: 26/03/2026. Orphan medicine